Square Pharmaceuticals PLC. (DSE:SQURPHARMA)

DSE:SQURPHARMA Income Statement

Financials in millions BDT. Fiscal year is July - June.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Revenue	80,128	76,288	70,101	60,708	57,598	50,703
Revenue Growth (YoY)	14.41%	8.83%	15.47%	5.40%	13.60%	10.52%
Cost of Revenue	41,893	40,377	37,548	32,473	28,719	25,470
Gross Profit	38,235	35,911	32,553	28,235	28,879	25,233
Selling, General & Admin	17,563	16,756	14,571	11,689	12,118	10,034
Other Operating Expenses	-57.31	-238.08	8.1	-144.4	-98.27	-69.57
Operating Expenses	17,506	16,518	14,579	11,545	12,019	9,965
Operating Income	20,729	19,393	17,974	16,690	16,860	15,269
Interest Expense	-177.53	-214.8	-244	-118.97	-0.03	-0.01
Interest & Investment Income	6,485	6,209	4,645	3,957	3,004	3,137
Earnings From Equity Investments	3,222	3,194	2,595	2,523	2,011	1,291
Currency Exchange Gain (Loss)	308.43	308.43	346.52	650.1	451.34	19.42
Other Non Operating Income (Expenses)	-	-	-	-	-	34.43
EBT Excluding Unusual Items	30,567	28,889	25,316	23,701	22,325	19,751
Gain (Loss) on Sale of Investments	-	-	-	-	384.59	177.04
Gain (Loss) on Sale of Assets	-	-	-	-79.8	53.49	-
Other Unusual Items	0.93	0.93	0.26	0.62	0.72	32.06
Pretax Income	30,568	28,890	25,316	23,622	22,764	19,960
Income Tax Expense	5,285	4,919	4,389	4,642	4,607	4,013
Earnings From Continuing Operations	25,283	23,971	20,927	18,980	18,157	15,947
Minority Interest in Earnings	-3.42	-3.12	-1.61	-0.24	0.03	-
Net Income	25,280	23,968	20,926	18,980	18,157	15,947
Net Income to Common	25,280	23,968	20,926	18,980	18,157	15,947
Net Income Growth	20.28%	14.54%	10.25%	4.53%	13.86%	19.42%
Shares Outstanding (Basic)	886	886	886	886	886	886
Shares Outstanding (Diluted)	886	886	886	886	886	886
Shares Change (YoY)	-0.01%	-	-	-	-	-
EPS (Basic)	28.52	27.04	23.61	21.41	20.48	17.99
EPS (Diluted)	28.52	27.04	23.61	21.41	20.48	17.99
EPS Growth	20.29%	14.54%	10.25%	4.53%	13.86%	19.42%
Free Cash Flow	14,555	11,125	14,348	5,685	6,692	7,178
Free Cash Flow Per Share	16.42	12.55	16.18	6.41	7.55	8.10
Dividend Per Share	12.000	12.000	11.000	10.500	10.000	6.000
Dividend Growth	9.09%	9.09%	4.76%	5.00%	66.67%	34.04%
Gross Margin	47.72%	47.07%	46.44%	46.51%	50.14%	49.77%
Operating Margin	25.87%	25.42%	25.64%	27.49%	29.27%	30.11%
Profit Margin	31.55%	31.42%	29.85%	31.26%	31.52%	31.45%
Free Cash Flow Margin	18.16%	14.58%	20.47%	9.37%	11.62%	14.16%
EBITDA	22,928	21,594	20,293	19,000	18,695	17,151
EBITDA Margin	28.62%	28.31%	28.95%	31.30%	32.46%	33.83%
D&A For EBITDA	2,199	2,201	2,319	2,310	1,835	1,882
EBIT	20,729	19,393	17,974	16,690	16,860	15,269
EBIT Margin	25.87%	25.42%	25.64%	27.49%	29.27%	30.11%
Effective Tax Rate	17.29%	17.03%	17.34%	19.65%	20.24%	20.10%
Revenue as Reported	-	-	-	-	57,598	50,703
Advertising Expenses	-	8.69	1.18	961.42	3.61	3.01

Source: S&P Global Market Intelligence. Standard template. Financial Sources.